US EditionBrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials
Summary by Eastern Progress
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
All
Left
Center
Right
BrainStorm Cell Therapeutics and Minaris partner on manufacturing NurOwn for trial
BrainStorm Cell Therapeutics has partnered with Minaris Advanced Therapies to manufacture NurOwn for an upcoming clinical trial.The post BrainStorm Cell Therapeutics and Minaris partner on manufacturing NurOwn for trial appeared first on Clinical Trials Arena.
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials
NEW YORK, May 27, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it has signed a Letter of Intent (LOI) with Minaris Advanced Therapies, a…
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
